Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials

2719 results

Sort By:

Postoperative Analgesia Using Ganglion Impar Block After Anal Surgery

Study ID: NCT04110132
Start Date: 2028-07-01
End Date: 2029-12-31
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

60

Intervention / Treatment

Ganglion impar block with Bupivacaine.

Ganglion impar block with normal saline

Sponsor

University of Alexandria

Source: clinicaltrials.gov

Share:
Add to list

BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)

Study ID: NCT07009899
Start Date: 2025-12-01
End Date: 2029-02-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

34

Intervention / Treatment

Linvoseltamab

Sponsor

Medical College of Wisconsin

Source: clinicaltrials.gov

Share:
Add to list

A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma

Study ID: NCT07120984
Start Date: 2026-01-30
End Date: 2029-01-30
Study Type

Interventional

Study Phase

Phase2

No. of Participants

52

Intervention / Treatment

L19TNF

L19TNF and TMZ

L19TNF and CCNU

L19TNF monotherapy

L19TNF and TMZ in recurrent astrocytoma

L19TNF and CCNU in recurrent astrocytoma

L19TNF monothery in recurrent oligodendroglioma

Sponsor

Philogen S.p.A.

Source: clinicaltrials.gov

Share:
Add to list

Pharmacist-Led Treat-to-Target Urate Lowering Therapy in Patients With Gout

Study ID: NCT06887452
Start Date: 2026-03-01
End Date: 2030-09-30
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

310

Intervention / Treatment

Pharmacist-Led

Sponsor

VA Office of Research and Development

Source: clinicaltrials.gov

Share:
Add to list

Effects of Various Cannabis Strains on Perceptual, Subjective and Objective Use Outcomes

Study ID: NCT07214155
Start Date: 2026-01-01
End Date: 2029-09
Study Type

Interventional

Study Phase

Phase1

No. of Participants

70

Intervention / Treatment

Cannabis

0 mg THC (placebo)

Sponsor

Johns Hopkins University

Source: clinicaltrials.gov

Share:
Add to list

A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

Study ID: NCT07175285
Start Date: 2025-11-04
End Date: 2032-11-01
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

223

Intervention / Treatment

Current standard of care treatment options

Sponsor

Bristol-Myers Squibb

Source: clinicaltrials.gov

Share:
Add to list

Unbound Cloxacillin Concentrations During Continuous Infusion

Study ID: NCT06848387
Start Date: 2025-12
End Date: 2027-12
Study Type

Interventional

Study Phase

Phase4

No. of Participants

25

Intervention / Treatment

Unbound cloxacillin concentration

Sponsor

Emeli Månsson

Source: clinicaltrials.gov

Share:
Add to list

Mesenchymal Stem Cells With Cooling Therapy for Infants With Hypoxic-Ischemic Encephalopathy

Study ID: NCT07018739
Start Date: 2026-06
End Date: 2033-12
Study Type

Interventional

Study Phase

Phase2

No. of Participants

40

Intervention / Treatment

Wharton's jelly-derived mesenchymal stem cells

0.9 % Normal Saline

Sponsor

Mahidol University

Source: clinicaltrials.gov

Share:
Add to list

Conventional Ultrafiltration Versus Dilutional Ultrafiltration in Pediatric CPB Patients

Study ID: NCT07221630
Start Date: 2026-01-01
End Date: 2027-01-02
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

100

Intervention / Treatment
Sponsor

Akron Children's Hospital

Source: clinicaltrials.gov

Share:
Add to list

Forward to Quit: A Person-centered Mobile Technology Intervention for Smoking Cessation Among Transgender Adults

Study ID: NCT07181551
Start Date: 2026-12
End Date: 2031-12
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

44

Intervention / Treatment

Forward to Quit (F2Q)

Sponsor

University of Colorado, Denver

Source: clinicaltrials.gov

Share:
Add to list